

# CME INSTITUTE

collective mindfulness

[#CKD Tweetorial #1: A Rationale for Treating CKD with Combination Therapy](#)

Feb 2<sup>nd</sup> 2023

[VIEW ON TWITTER](#)

## ACCREDITATION STATEMENT

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

## FACULTY AFFILIATIONS

**Erin Michos, MD, MHS**

Johns Hopkins School of Medicine  
Baltimore, Maryland

**Joel Topf, MD, FACP**

Beaumont Hospital  
Grosse Pointe, MI

## FINANCIAL DISCLOSURE

The CME Institute adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). Any individuals in a position to control the content of a continuing education activity, including faculty, content developers, reviewers, staff, and others, are required to disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.


The CME Institute has mitigated all relevant conflicts of interest prior to the commencement of the activity. None of the individuals involved in the content have relevant financial relationships with ineligible companies except the following:

**Dr Michos** has served on the speakers/advisory boards for Astra Zeneca, Bayer, Boehringer Ingelheim, and Novartis.

**Dr Topf** has received grant/research support from Natera; has received honoraria for speaking/teaching from AstraZeneca; has served on advisory boards for Tricida, Vifor, Cara, Bayer and AstraZeneca.

**Michael R. Page, PharmD, RPh**

Independent Medical Director/Medical Writer  
Plainsboro, New Jersey



# CME INSTITUTE

collective mindfulness

**Dr. Page** is a consultant for BioCentric, Inc. and American Medical Communications, Inc.

**Susan B. Nicholas, MD, MPH, PhD**

Peer Review

Professor of Medicine, Divisions of Nephrology; Endocrinology, Diabetes and Metabolism  
UCLA  
Los Angeles, CA

**Dr. Nicholas** has received consulting fees from Bayer AG, Boehringer Ingelheim/Lilly; received grant/research support from Bayer AG, Goldfinch Bio, Travere and Terasaki Institute of Biomedical Innovation; received honoraria for speaking/teaching from AstraZeneca, Bayer AG, Boehringer Ingelheim/Lilly; and received advisory board fees from Bayer AG, Gilead, NovoNordisk, Boehringer Ingelheim/Lilly.

None of the other planners, reviewers, and CME Institute staff for this educational activity have relevant financial relationships with ineligible companies to disclose. All relevant financial relationships have been mitigated.

## TWEETORIAL REFERENCES

### Tweet #7

Mende CW. Chronic kidney disease and SGLT2 inhibitors: a review of the evolving treatment landscape. *Adv Ther.* 2022;39(1):148-164.

### Tweet #8

Centers for Disease Control and Prevention. Chronic kidney disease in the United States, 2021. <https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html> Accessed December 17, 2022.

### Tweet #9


Mende CW. Chronic kidney disease and SGLT2 inhibitors: a review of the evolving treatment landscape. *Adv Ther.* 2022;39(1):148-164.

### Tweet #10

Kintscher U, Bakris GL, Kolkhof P. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. *Br J Pharmacol.* 2022;179(13):3220-3234.

### Tweet #11

Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. *Eur Heart J.* 2022;43(6):474-484.



# CME INSTITUTE

collective mindfulness

## **Tweet #12**

Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. *Eur Heart J*. 2022;43(6):474-484.

## **Tweet #13**

Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. *N Engl J Med*. 2020;383:2219-2229.

Finerenone [Package Insert].

<https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fc7267655d5a-496e-b037-b847bda9fb7c>. Accessed December 23, 2022.

## **Tweet #14**

Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. *Eur Heart J*. 2022;43(6):474-484.

## **Tweet #15**

Agarwal R, Joseph A, Anker SD, et al. Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial. *J Am Soc Nephrol*. 2022;33(1):225-237.

## **Tweet #16**

Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med*. 2019;380:2295-2306.


Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. *N Engl J Med*. 2020;383:1436-1446.

## **Tweet #17**

Li N, Lv D, Zhu X, et al. Effects of SGLT2 inhibitors on renal outcomes in patients with chronic kidney disease: a meta-analysis. *Front Med (Lausanne)*. 2021;8:728089.

## **Tweet #18**

Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. *Eur Heart J*. 2021;43(6):474-484.



# CME INSTITUTE

collective mindfulness

## **Tweet #19**

Trujillo JM, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. *Ther Adv Endocrinol Metab.* 2021;12:2042018821997320.

## **Tweet #20**

Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomized trials. *Lancet Diabetes Endocrinol.* 2021;9(10):653-662.

## **Tweet #21**

Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomized trials. *Lancet Diabetes Endocrinol.* 2021;9(10):653-662.


Chen J-J, Wu C-Y, Jenq C-C, et al. Association of glucagon-like peptide-1 receptor agonist vs dipeptidyl peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease. *JAMA Netw Open.* 2022;5(3):e221169.

## **Tweet #22**

American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, et al. 11. Chronic kidney disease and risk management: standards of medical care in diabetes - 2022. *Diabetes Care.* 2022;45(Suppl 1):S175-S184.

## **Tweet #23**

American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, et al. 11. Chronic kidney disease and risk management: standards of medical care in diabetes - 2022. *Diabetes Care.* 2022;45(Suppl 1):S175-S184.



# CME INSTITUTE

collective mindfulness

## GLOSSARY

CKD - Chronic Kidney Disease

CV - Cardiovascular

CVD - Cardiovascular Disease

EGFR - Estimated Glomerular Filtration Rate

ESKD - End-Stage Kidney Disease

GLP-1 RA - Glucagon-Like Peptide-1 Receptor Agonist

MACE - Major Adverse Cardiovascular Events

MRA -Mineralocorticoid Receptor Antagonist

SGLT2 - Sodium-glucose cotransporter-2

T2DM - Type 2 diabetes mellitus

UACR - Urine albumin-creatinine ratio